The US clinical trial “MMP2, MMP9 and NGAL as Biomarkers for Glioblastoma (GBM) Biomarkers for the Prognosis of Glioblastoma (NCT01493219)” has been sponsored by University of Nebraska started since 2011. Here, MMP2 is linked to glioblastoma.